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BACKGROUND: The World Health Organization recommends that
human growth should be monitored with the use of international stan-
dards. However, in obstetric practice, we continue to monitor fetal growth
using numerous local charts or equations that are based on different
populations for each body structure. Consistent with World Health Orga-
nization recommendations, the INTERGROWTH-21st Project has produced
the first set of international standards to date pregnancies; to monitor fetal
growth, estimated fetal weight, Doppler measures, and brain structures; to
measure uterine growth, maternal nutrition, newborn infant size, and body
composition; and to assess the postnatal growth of preterm babies. All
these standards are based on the same healthy pregnancy cohort.
Recognizing the importance of demonstrating that, postnatally, this
cohort still adhered to the World Health Organization prescriptive
approach, we followed their growth and development to the key milestone
of 2 years of age.
OBJECTIVE: The purpose of this study was to determine whether the
babies in the INTERGROWTH-21st Project maintained optimal growth and
development in childhood.
STUDY DESIGN: In the Infant Follow-up Study of the INTERGROWTH-
21st Project, we evaluated postnatal growth, nutrition, morbidity, and
motor development up to 2 years of age in the children who contributed
data to the construction of the international fetal growth, newborn infant
size and body composition at birth, and preterm postnatal growth stan-
dards. Clinical care, feeding practices, anthropometric measures, and
assessment of morbidity were standardized across study sites and
documented at 1 and 2 years of age. Weight, length, and head circum-
ference age- and sex-specific z-scores and percentiles and motor
development milestones were estimated with the use of the World Health
Organization Child Growth Standards and World Health Organization
milestone distributions, respectively. For the preterm infants, corrected
age was used. Variance components analysis was used to estimate the
percentage variability among individuals within a study site compared with
that among study sites.
RESULTS: There were 3711 eligible singleton live births; 3042 children
(82%) were evaluated at 2 years of age. There were no substantive dif-
ferences between the included group and the lost-to-follow up group.
Infant mortality rate was 3 per 1000; neonatal mortality rate was 1.6 per
1000. At the 2-year visit, the children included in the INTERGROWTH-21st
Fetal Growth Standards were at the 49th percentile for length, 50th
percentile for head circumference, and 58th percentile for weight of the
World Health Organization Child Growth Standards. Similar results were
seen for the preterm subgroup that was included in the INTERGROWTH-
21st Preterm Postnatal Growth Standards. The cohort overlapped be-
tween the 3rd and 97th percentiles of the World Health Organization motor
development milestones. We estimated that the variance among study
sites explains only 5.5% of the total variability in the length of the children
between birth and 2 years of age, although the variance among individuals
within a study site explains 42.9% (ie, 8 times the amount explained by the
variation among sites). An increase of 8.9 cm in adult height over mean
parental height is estimated to occur in the cohort from low-middle income
countries, provided that children continue to have adequate health,
environmental, and nutritional conditions.
CONCLUSION: The cohort enrolled in the INTERGROWTH-21st
standards remained healthy with adequate growth and motor devel-
opment up to 2 years of age, which supports its appropriateness for
the construction of international fetal and preterm postnatal growth
standards.
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A lthough human growth, fromcell to whole body, is recognized
as a universal biologic process, some
entrenched views persist regarding fetal
growth, in particular that it should be
compared with a site-speciﬁc rather
than prescriptive population. This view
is not held by the World Health
Organization (WHO) or by the Centers
for Disease Control & Prevention,1,2
which recommend using international
neonatal standards. Likewise, such
standards have now been adopted
to estimate the burden and conse-
quences of babies being born small for
gestational age in low- and middle-
income countries.3
We have summarized the key statisti-
cal, physiologic, ethnic, and genetic
evidence relating to this issue.4,5 Practi-
cally, the debate focuses on whether it is
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correct to monitor fetal growth using 1
of the many site-speciﬁc charts available.
Typically, such charts are based on
different populations for each fetal body
structure and have been developed at
hospital level.4 These multiple, site-
speciﬁc charts are references, not inter-
national standards that are used
commonly inmost other areas of biology
and medicine.
This neglected aspect of obstetric
practice means that clinical decisions
are made based on reference charts that
were derived from a wide range of
different study populations. For example,
a woman may have an early gestational
age assessment with the use of a fetal
crown-rump length chart based on a
study of 80 women from Glasgow,
Scotland,6,7 followed by a clinical assess-
ment with the use of a fundal height chart
based on 313 women from Cardiff,
Wales.8 Fetal biometry valuesmay thenbe
compared with 1 of many local charts,9
and, during the same ultrasound scan,
estimated fetal weightmay be determined
from an equation based on 109 fetuses
studied in Texas during the 1980s,10,11
complemented by a recent chart from
other US populations.12
If the woman requires further assess-
ment, the umbilical Doppler measures
are judged with the use of yet another
reference population.13 At birth, the
anthropometricmeasures of the newborn
infant could be evaluatedwith the use of a
multiplicity of reference charts, all of
which are totally unrelated to the fetal
growth charts that were being used just a
few weeks earlier.
The INTERGROWTH-21st Project
aimed to resolve these issues byconducting
studies of human growth and develop-
ment that involved pregnant women who
were enrolled at <14 weeks gestation
speciﬁcally to monitor their fetuses,
newborn infants, and children prospec-
tively up to 2 years of age to generate a
single set of international standards to
make judgements on the growth of all
humans.14 The studies were based
conceptually on the WHO prescriptive
approach to constructing human
growth standards.15 The study pop-
ulations across geographically delimited
areas were selected because they had the
recommended health, nutrition, and
socioeconomic status that was required to
construct international standards.15
Hence, the INTERGROWTH-21st
Standards (from maternal weight gain,
to pregnancy dating, fetal growth and
estimated fetal weight, to brain struc-
tures, amniotic ﬂuid volume, umbilical
artery Doppler measures, and newborn
body composition) are prescriptive
because they are based on a cohort of
“healthy” pregnancies and babies from
the same geographically selected pop-
ulations in which most of the health
and nutritional needs of mothers were
met and adequate antenatal care
provided.
Nevertheless, the question always
remains with studies that are focused on
fetal growth as to how “healthy” were
these children after birth and during
childhood (ie, are they truly healthy?).
We took this question seriously very
early in the planning of the project and
added a clinical and developmental
follow-up evaluation16-18 beyond the
customary early neonatal period as a
further criterion to support the assertion
that INTERGROWTH-21st babies
represent true standard populations.19
The key milestone of 2 years of age was
identiﬁed as a realistic and biologically
relevant time point.20
Hence, we ﬁrst compared the
INTERGROWTH-21st Standards4,21,22
with the WHO Child Growth Stan-
dards.23 We demonstrated that, during
the early neonatal period, the partici-
pants who were selected were appro-
priate and met the WHO prescriptive
criteria for optimal growth.15 We then
extended, for the ﬁrst time in this liter-
ature, the prescriptive evaluation by
designing the Infant Follow-up Study of
the INTERGROWTH-21st Project.
This study aimed to evaluate the
growth, nutrition, morbidity, and motor
development at 2 years of age of the
infants who were included in the inter-
national fetal and preterm growth stan-
dards to reinforce their prescriptive
nature against which fetuses and
preterm infants worldwide can now be
compared.
Materials and Methods
INTERGROWTH-21st was a multi-
center, population-based project that
was conducted between 2009 and 2016
in 8 locations: Pelotas, Brazil; Turin,
Italy; Muscat, Oman; Oxford, UK; Seat-
tle, WA; Shunyi County, Beijing, China;
the central area of Nagpur, India, and
the Parklands suburb of Nairobi,
Kenya.14,24
The primary aim of the project was to
study growth, health, nutrition, and
neurodevelopment from <14 weeks
gestation to 2 years of age.14 In the Fetal
Growth Longitudinal Study of the
INTERGROWTH-21st Project,21 we
recruited women from these 8 pop-
ulations who initiated antenatal care at
<14 weeks gestation and who met the
entry criteria of optimal health, nutrition,
education, and socioeconomic status.14
Gestational age was estimated based
on the date of the last menstrual period
and corroborated by ultrasound mea-
surement of crown-rump length at 9þ0
to 13þ6 weeks gestation with the use of a
standard protocol. All fetuses in the Fetal
Growth Longitudinal Study were eligible
to contribute data to the construction of
the international fetal growth standards;
all infants who were born at <37 weeks
gestation in the Fetal Growth Longitu-
dinal Study were eligible to contribute
data to the construction of the interna-
tional Postnatal Growth Standards for
Preterm Infants. At each postnatal visit, a
record of any illnesses in the preceding
months was noted in addition to
anthropometric measurements and a
developmental assessment.
Weight, length, and head circumfer-
ence were obtained within 12 hours
(and no >24 hours) of birth on the
postnatal wards and at follow-up visits
that were scheduled at 1 and 2 years of
age (1 month). Measurements were
taken exclusively by the same teams who
were trained and standardized at regular
intervals for the INTERGROWTH-21st
Project.25
All study sites used the same methods
and equipment: electronic scales
(Seca, Hangzhou, China) for weight
(sensitivity of 10 g to 20 Kg); a specially
designed Harpenden infantometer
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(Chasmors Ltd, London, UK) for
recumbent length, and a metallic non-
extendable tape (Chasmors Ltd) for head
circumference.26,27 Measurement pro-
cedures were standardized according to
WHO recommendations.28 During the
central standardization sessions for
anthropometrists, the intra- and inter-
observer error of measurement values
for recumbent length ranged from
0.3e0.6 cm and for head circumference
from 0.2e0.5 cm.25
Measurements were taken twice,
independently, by 2 of the study anthro-
pometrists. If the difference between
the 2 measures exceeded for weight 50 g
for newborn infants and 100 g at 1 and
2 years of age (length, 7 mm; head
circumference, 5 mm), then both ob-
servers independently repeated that
measurement a second time and, if
necessary, a third time.25,27
When the Infant Follow-up Study
started, some enrolled children had
passed their second birthday already.
The families of these children were
invited to a follow-up visit with the
maximum age at assessment for the child
being 27 months. Similarly, those chil-
dren who already had passed their ﬁrst
birthday, but were <2 years old, were
invited initially for the ﬁrst visit up to the
age of 18 months. In total, only 14% of
1- and 2-year visits occurred outside the
protocol-designated age range for
assessment.
Detailed information was obtained
from the mother about the infant’s
health, severe morbidities, length of
breastfeeding, timing of the introduction
of food, feeding practices, and food
intake with the use of standardized
forms that were produced especially for
the project (www.intergrowth21.org).
WHO protocols were followed to
assess motor development milestones.29
We focused on 4 WHO milestones that
are less likely to be affected by recall bias:
sitting without support, hands and knees
crawling, standing alone, and walking
alone. Data were collected by trained
staff using a form with pictures of the
relevant child positions and corre-
sponding deﬁnitions. Parents were asked
to report the age in months and weeks
when they ﬁrst observed or “never
observed” the milestones (http://www.
intergrowth21.org.uk).
We collected the same information
from parents at 1 and 2 years of age to
evaluate the consistency of the reported
dates. There were 7965 pairs of values
recorded at year 1 and the year 2
interviews, of which 92.6% were iden-
tical at both visits. Among the 588
discrepant values, the median difference
ranged between e1 week (interquartile
range, 4.3e4.3) for hands and knees
crawling to e0.2 weeks (interquartile
range, e6.3e2.3) for standing alone. In
these cases, after investigation, the values
that were obtained at the 1-year visit
were used.
Across all study sites, standardized
clinical care and feeding practices
were implemented based on protocols
that were developed by the
INTERGROWTH-21st Neonatal Group
(http://www.intergrowth21.org.uk).30-32
Exclusive breastfeeding up to 6 months
was promoted for all babies, with sup-
plementation for preterm infants as
recommended.30,33,34
Age- and sex-speciﬁc z-scores and
percentiles were estimated for each child
at 2 years of age comparing their weight,
length, and head circumference to the
WHO Child Growth Standards.35 Cor-
rected age was used for the preterm
subgroup.36 Four values (3 for weight
and 1 for head circumference) were
above or below 5 standard deviations
(SD) of themean of the study population
and were excluded.
Variance components analysis was
performed to calculate the percentage of
variance in infant length at birth, 1, and 2
years because of between- and within-
site variance. A multilevel mixed effects
model was ﬁtted with random intercepts
for the study site and individual levels
(with individuals nested within sites).
The model, which was ﬁtted with un-
structured covariance structure, was
adjusted by age (after fractional poly-
nomial transformation) and sex. Both
age and sex were treated as ﬁxed effects.
We analyzed 2026 mother-father-
infant trios to compare the “mean
parental height” with a predicted adult
height for each infant, deﬁned as twice
their length at 2 years of age.37
For infants reported to have achieved
the milestones, the proportions within
the WHO motor development windows
of achievement35 were estimated, and
z-scores were calculated by subtraction of
themedian age of achievement reported in
theWHOmotor development study from
the median age of achievement in our
cohort, and division by the SD in the
WHO motor development study. Cor-
rected age was used for the preterm
subgroup.
The proportion of infants who
received breast milk and vitamin and
mineral supplements and those who
followed a special diet were estimated at
1 and 2 years of age.38,39
We used Stata software (version 12;
StataCorp, College Station, TX). Data
were entered locally into the specially
developed online data management
system (http://medscinet.com).40
The INTERGROWTH-21st Projectwas
approved by the Oxfordshire Research
Ethics Committee “C” (reference: 08/
H0606/139), the research ethics com-
mittees of the individual institutions, and
the regional health authorities where the
project was implemented. Participants
provided written consent to be involved
in the study.
Results
Population characteristics
There were 4321 singleton newborn in-
fants who were alive at birth without
congenital malformations whose
mothers were recruited at <14 weeks
gestation and included in the cohort of
the international INTERGROWTH-21st
fetal growth standards.21 Among these,
183 infants were lost to follow up or
withdrew consent during pregnancy;
298 infants were ineligible for the Infant
Follow-up Study because the study site
in Seattle, WA, could not participate.
There were 6 neonatal deaths before
hospital discharge (neonatal mortality
rate, 1.6/1000 live births), 1 congenital
malformation that was detected after
birth, and 5 infant deaths, which repre-
sented a total infant mortality rate of 3
per 1000 live births. In addition, 103
mothers withdrew consent early in the
study. Finally, 14 infants were >27
months old at the time the follow-up
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started; they therefore were not invited
to participate. Hence, 3711 newborn
infants were eligible for the Infant
Follow-up Study, of these, 669 infants
were lost to follow up. Thus, the total
cohort that was studied comprised 3042
infants (Figure 1) who represented 82%
of those eligible (86% for the preterm
subgroup, 143/166; Supplementary
Figure).
The means (SD) of the age at which
measures were obtained were 24.41.2
and 23.20.7 months for the total
cohort and the preterm subgroup,
respectively; 86% of the 2-year measures
were obtained from 23e25 months for
the total cohort and 93% were obtained
for the preterm subgroup.
The neonatal characteristics of the in-
fants divided into those that completed
the 2-year follow-up evaluations
(n¼3042) and those lost to follow up
(n¼669) are presented in Table 1. Both
groups were similar in terms of anthro-
pometric measures at birth and neonatal
morbidity. A similar comparison within
the preterm subgroup is presented in
Table 2.
Feeding practices
At hospital discharge, 89% of the total
cohort and 74% of the preterm sub-
group were exclusively breast-milk fed.
Similar patterns were seen among the
children who were lost to follow-up at
2 years of age. Exclusive breastfeeding
was stopped at a median of 5 months
(interquartile range, 3e6 months); this
was similar in the preterm subgroup.
Breastfeeding stopped entirely at a
median of 12 months (interquartile
range, 6e18 months) for the total
cohort and 11 months (interquartile
range, 5e18 months) for the preterm
subgroup.
In the total cohort, the proportion of
children who still were receiving breast
milk fell from 59% at 1 year to 11% at 2
years, by which time 34% of the children
were formula fed. All children received
dairy products of some type (including
human milk) at both ages. Food sup-
plements had been given routinely to
33% of children by 1 year and 21% by 2
years. At 1 year of age, 51% of the infants
in the preterm subgroup were still
receiving breast milk; the ﬁgure fell to
8% at 2 years, by which time 34% of
children were receiving formula. Food
supplements that included vitamins and
minerals were given to 36% of the in-
fants in the ﬁrst year and 28% of the
infants by the second year in the preterm
cohort. Complementary feeding prac-
tices were considered appropriate in
terms of diversity, the timing of intro-
duction, and the food variety across sites
(Supplementary Tables 1 and 2).34
Postnatal morbidity
The overall morbidity rate in the total
cohort was low (Table 3); only 9% of
infants were hospitalized (median
length of stay, 3 days) in the second
year of life. The most frequently re-
ported or diagnosed conditions were
acute respiratory infections, diarrhea,
and/or gastrointestinal problems with
few repeated episodes, skin problems,
and febrile episodes. Antibiotics were
prescribed on >3 occasions in 10.9%
and 15.8% of children in the ﬁrst and
FIGURE 1
Study flow of the INTERGROWTH-21st Infant Follow-up Study
The chart indicates the cohort that contributed data to the construction of the INTERGROWTH-21st
Fetal Growth Standards.21
CM, congenital malformation; USA, United States of America.
Villar et al. Validation of the INTERGROWTH-21st fetal growth standards. Am J Obstet Gynecol 2018.
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second years, respectively, which cor-
responds closely to the rate of reported
fever episodes (Table 3). Similar pat-
terns were seen in the preterm sub-
group (Table 4). Most of the infants
were fully vaccinated in accordance
with recommended policies.
Growth and development from birth
to 2 years of age
At 1 year of age, a comparison of the total
cohort with the age- and sex-speciﬁc
WHO Child Growth Standards showed
that length and head circumference had
a mean SD z-score of 0.01.1 for both
measures and that the medians were at
the 49th and 48th percentiles of the
WHO Child Growth Standards, respec-
tively; for weight, the mean z-score was
0.21.1 and median at the 58th
percentile.
At the 2-year visit, the growth of the
children who were included in the
INTERGROWTH-21st Fetal Growth
Standards plotted almost perfectly onto
the WHO Child Growth Standards (ie,
93% for length, 91% for weight [with the
expected larger variability], and 92% for
head circumference, respectively. Our
cohort’s values were within the 3rd and
97th cut-off points of the WHO Child
Growth Standards (Table 5; Figure 2).
For length and head circumference, the
mean SD z-score was 0.01.1 for both
measures, and the medians were at the
49th and 50th percentiles of the WHO
Child Growth Standards, respectively.
For weight, the mean  SD z-score was
0.21.1, and median was at the 58th
percentile. Figure 2 also shows the 3rd,
50th and 97th percentiles of the distri-
butions of our data (the same percentiles
of theWHOChild Growth Standards are
included in Figure 2 at years 1 and 2). As
shown, the percentiles from our popu-
lation are almost identical to those of the
WHO standards.
At 1 year of age, a comparison of the
preterm cohort only with the age- and
sex-speciﬁc WHO Child Growth Stan-
dards at postnatal corrected age, length,
and head circumference had a mean
z-score of 0.1 for both measures; the
medians were at the 52nd percentiles of
the WHO Child Growth Standards; for
weight, the mean  SD z-score was
0.21.1, and the median was at the 57th
percentile.
At 2 years of age, the growth of the
children who were included in the
INTERGROWTH-21st Preterm Post-
natal Growth Standards also plotted
similarly onto the WHO Child Growth
Standards (Table 6; Figure 2). For length
and head circumference, the mean SD
z-scores were -0.11.2 and 0.01.1,
respectively, and the median was at the
47th percentile for head circumference
of theWHOChild Growth Standards for
both measures. For weight, the mean
 SD z-score was 0.21.1, and the me-
dian was at the 53rd percentile.
The mean postnatal ages, at which the
4mainWHOmilestones for grossmotor
development29 were achieved for the
total cohort and preterm subgroup
(chronologic and corrected age) are
presented in Figure 3. Both groups
overlapped well for these milestones at
the 50th, 3rd, and 97th percentiles of the
WHO range for normal term infants. By
2 years of age,>99% of the children had
achieved the 4 motor development
milestones with >97% within the range
of the WHO milestones (data not
shown). However, although the preterm
subgroup overlapped very well when
corrected age was used, they displayed a
delay of approximately 1 month in
achieving the “walking alone” and
“standing alone” milestones, when esti-
mated age after birth was used
(Figure 3).
The variability in children’s length
among study sites compared with
that among individuals within a
study site
Maintaining the same analytic approach
to the 2-year follow-up data that was
TABLE 1
Neonatal characteristics of children who were included in the
INTERGROWTH-21st Fetal Growth Standards21 whowere evaluated at 2 years
of age compared with children who were lost to follow-up
Characteristic
Evaluated at 2 years
of age (n¼3042)
Not evaluated at
2 years of agea (n¼669)
Gestational age at
delivery, wkb
39.41.4 39.41.4
Birthweight, kgb 3.20.5 3.20.5
Birth length, cmb 49.12.0 49.22.0
Head circumference, cmb 33.71.4 33.91.3
Apgar at 5 minb 9.60.6 9.70.6
Age at hospital
discharge, dc
3 (2e4) 2 (1e4)
Early preterm, <34 wk
gestation, n (%)
18 (0.6) 3 (0.4)
Boys, n (%) 1516 (49.8) 324 (48.4)
Neonatal intensive care unit
stay >1 d but <3 d, n (%)
160 (5.3) 35 (5.2)
Hyperbilirubinemia, n (%) 137 (4.5) 37 (5.5)
Respiratory distress
syndrome, n (%)
51 (1.7) 15 (2.2)
Transient tachypnea of the
newborn infant, n (%)
65 (2.1) 15 (2.2)
Exclusive breastfeeding
at discharge, n (%)
2698 (88.8) 591 (88.5)
a Children lost to follow-up before evaluation at 2 years of age; b Data are meansstandard deviation; c Data are given as
median (interquartile range).
Villar et al. Validation of the INTERGROWTH-21st fetal growth standards. Am J Obstet Gynecol 2018.
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adopted for the fetus and newborn in-
fant,4,16,37 we summarized the variability
in skeletal growth and size during preg-
nancy, at birth, and in infancy and
childhood (ie, quantifying the variability
among study sites, as opposed to that
among individuals within a given site).
We estimated that the variance among
our study sites from birth through 1e2
years of age explains only 5.5% of the
total variability in length between birth
and 2 years of age; the variance among
individuals within a study site explains
42.9% (ie, 8 times the amount after we
controlled for age and sex). In Table 7,
we compared the present results with the
previously published INTERGROWTH-
21st data from the ﬁrst trimester of
pregnancy to 2 years of age. In all these
periods of rapid growth, the variance
among sites explains <10% of the total
variability in skeletal growth.
Estimated adult height of the
children included in the
INTERGROWTH- 21st fetal
growth standards
We estimated the difference between
the observed mean parental height and
the expected mean adult height (equal
to approximately double the mean
length at 2 years of age).37 In the study
sites in low-middle income countries
(n¼1611), an increase in mean
expected adult height of 8.9 cm over
mean parental height is predicted to
occur in a single generation, provided
that infants and children are exposed
to adequate health, environmental
and nutritional conditions from
early pregnancy onwards (Figure 4).
Conversely, in high-income country
sites (N¼415), this cohort will be on
average 2.2 cm taller than their parents
(Figure 4).
Comment
Main findings
The participants included in the con-
struction of the Fetal Growth Standards,
the Newborn Size at Birth and the Pre-
term Postnatal Growth Standards of the
INTERGROWTH-21st Project were
selected during early pregnancy specif-
ically to generate international stan-
dards.15 The comprehensive data
presented here, which describe for
the ﬁrst time the postnatal physical
growth, infant mortality rate, morbidity
and motor development of the
INTERGROWTH-21st participants,
corroborate that they conformed to the
WHO prescriptive approach for the
construction of human growth stan-
dards. They are a cohort with continuous
very low rates of clinical conditions that
could affect optimal growth and
development.
Our ﬁndings reinforce the a priori
concept17 that it is possible to identify a
subset of mostly moderate and late pre-
term infants, with no evidence of intra-
uterine growth restriction and limited
neonatal morbidity,41 which constitutes
an adequate approximation (in terms of
growth, health, nutrition, and develop-
ment) to a prescriptive population for
the construction of preterm postnatal
growth standards up to 64 weeks post-
menstrual age, the time at which they
match the WHO Child Growth
Standards.22,23
Strengths and limitations of the
study in the context of the
existing literature
As far as we are aware, this is the ﬁrst
time that a fetal cohort that has been
included in longitudinal studies for the
speciﬁc purpose of constructing pre-
scriptive growth standards has been
evaluated up to 2 years of age. Most ul-
trasound studies that aimed to create
reference charts for fetal growth have not
reported any postnatal assessment, nor is
it likely that such an assessment has been
carried out, given the time that has
elapsed since these studies were con-
ducted.9 We selected the 2-year mile-
stone because nutrition indicators that
are measured at this age are strongly
predictive of adult measures of nutrition,
TABLE 2
Neonatal characteristics of children who were included in the
INTERGROWTH-21st Preterm Postnatal Growth Standards22 who were
evaluated at 2 years of age compared with children lost to follow-up
Characteristic
Evaluated at 2 years
of age (n¼143)
Not evaluated at
2 years of agea (n¼24)
Gestational age at
delivery, wkb
35.51.6 35.71.4
Birthweight, kgb 2.50.5 2.40.5
Birth length, cmb 45.72.7 45.62.3
Head circumference, cmb 31.81.7 31.81.5
Apgar at 5 minb 9.20.9 9.21.2
Age at hospital
discharge, dc
4 (2e9) 4 (2e7)
Early preterm, <34 weeks
gestation, n (%)
19 (13.3) 3 (12.5)
Boys, n (%) 73 (51.0) 8 (33.3)
Neonatal intensive care unit
stay >1 but <3 d, n (%)
59 (41.3) 11 (45.8)
Hyperbilirubinemia, n (%) 29 (20.3) 3 (12.5)
Respiratory distress
syndrome, n (%)
20 (14.0) 6 (25.0)
Transient tachypnea of
the newborn infant, n (%)
23 (16.1) 1 (4.2)
Exclusive breastfeeding
at discharge, n (%)
106 (74.1) 19 (79.2)
a Children lost to follow-up before evaluation at 2 years of age; b Data are given as meanstandard deviation; c Data are given
as median (interquartile range).
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human capital, attained height, and in-
telligence.42 Before the age of 2 years, it
has been shown that children often cross
growth percentiles, whereas after this age
the phenomenon known as “growth
channelization” has been demonstrated,
because children tend to grow along the
same percentile.20
Our unique data are derived from a
prospective follow-up evaluation of in-
dividuals from 7 different regions of the
world from the ﬁrst trimester of
pregnancy to 2 years of age. These
ﬁndings strengthen the case for the
worldwide use of the international
INTERGROWTH-21st standards that
complement the WHO Child Growth
Standards in postnatal life. The similar-
ities between the INTERGROWTH-21st
and WHO studies mean that the size of
children, measured at 2 years of age, who
were born to healthy mothers, with
adequate nutrition, from healthy pop-
ulations at low risk of adverse pregnancy
outcomes, is consistent between the
studies and across time.
Other strong features of the study
include careful standardization of the
outcome measures and the comprehen-
siveness of the standardized clinical and
developmental assessments at 2 years of
age.43 Furthermore, we followed 82% of
the children and up to 86% of the pre-
term subgroup, which are excellent rates
for free-living urban subjects. Baseline
similarities between the infants who
were evaluated and those lost to follow-
up demonstrate that selection bias is very
unlikely to have inﬂuenced the observed
results.
We acknowledge some limitations
that relate to practical difﬁculties of
carrying out such a large, multicenter
study.
First, the information on morbidity
refers mostly to substantive clinical epi-
sodes, and data on gross motor devel-
opment were obtained from parental
report rather than direct observation;
however, we informed parents about the
Infant Follow-up Study protocol at
enrolment and asked them to record
severe conditions and infant develop-
mental milestones. In addition, parents
were encouraged to bring sick children
for care to the participating centers;
illness therefore was recorded at the time
of the event.
Second, the study outcomes do not
extend >2 years of age. This juncture
was selected because it is a key time for
the detection of postnatal growth
faltering,44,45 and an anthropometric
and clinical evaluation at this age is a very
good predictor of subsequent growth.
Finally, the Seattle, WA, study site did
not participate in the follow-up of chil-
dren because of logistic issues that were
associated with this inner city, highly
mobile population. Although they
TABLE 3
Morbidity in the previous year of children who were included in the
INTERGROWTH-21st Fetal Growth Standards21 at 1 and 2 years of age
Medical condition
1 Year of age
(n¼2834), n (%)
2 Years of age
(n¼3042), n (%)
Hospitalized at least once 344 (12.1) 272 (8.9)
Total no. of days hospitalized 3 (1e5)a 3 (1e5)a
Any prescription made by a
healthcare professional
1783 (62.9) 1911 (62.9)
Antibiotics (3 regimens) 308 (10.9) 481 (15.8)
Iron/folic acid/vitamin
B12/other vitamins
815 (28.8) 430 (14.1)
Up-to-date with local
vaccination policies
2607 (92.0) 2903 (95.4)
Otitis media/pneumonia/
bronchiolitis
228 (8.0) 293 (9.6)
Parasitosis/diarrhea/vomiting 148 (5.2) 139 (4.6)
Seizures/cerebral palsy/
neurologic disorders
9 (0.3) 9 (0.3)
Exanthema/skin disease 456 (16.1) 399 (13.1)
UTI/pyelonephritis 4 (0.1) 10 (0.3)
Fever 3 d (3 episodes) 293 (10.3) 309 (10.2)
Malaria 13 (0.5) 12 (0.4)
Meningitis 5 (0.2) 0 (0.0)
Other infections that
required antibiotics
69 (2.4) 79 (2.6)
Hearing problems 4 (0.1) 3 (0.1)
Asthma 24 (0.8) 42 (1.4)
Cardiovascular problems 9 (0.3) 7 (0.2)
Blindness 6 (0.2) 4 (0.1)
Gastroesophageal reflux 88 (3.1) 9 (0.3)
Any hemolytic condition 14 (0.5) 22 (0.7)
Any malignancy 3 (0.1) 6 (0.2)
Cow’s milk protein allergy NA 21 (0.7)
Food allergies NA 52 (1.7)
Injury trauma 43 (1.5) 130 (4.3)
Any condition that required surgery 31 (1.1) 34 (1.1)
NA, not applicable (data were not collected at the 1-year follow-up visit); UTI, urinary tract infection.
a Data are given as median (interquartile range).
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represented only 298 newborn infants
of more than 4000 in the total cohort
and it is very unlikely that they
would have affected the overall results
presented here, it would have been
better to have studied this subsample
as well.
The WHO motor development
assessment is a simple, pragmatic, and
reliable tool to describe normal variation
in the achievement of milestones that are
reached progressively across infancy. It is
especially recommended for studying a
large number of infants at the cohort
level, rather than individual level.35 We
have observed that, using chronologic
age, gross motor indicators for 2-year-
old children who were born preterm
(despite being always within WHO rec-
ommended windows) are below those of
the total cohort by approximately 1
month. This pattern disappears with the
use of corrected age (Figure 3). Thus, it is
likely that the true range of development
in uncomplicated preterm infants is be-
tween chronologic and corrected age.
However, it is possible that levels of
preterm postnatal development may be
associated with etiologic phenotypes, as
was shown with early neonatal
morbidity.41 We presently are studying
these issues in the INTERBIO-21st Study,
which is the extension to the
INTERGROWTH-21st Project.
In all the INTERGROWTH-21st
publications, we have emphasized that
the relevant question when comparing
growth across populations is whether the
variability in skeletal growth within a
population (interindividual genetic dif-
ference) is larger than the variability
among populations (interpopulation
genetic difference) when nutritional and
health needs are met.
We have used variance components
analysis in cohorts that were followed
prospectively to identify the propor-
tional contribution of the within and
between sites variance compo-
nents.4,16,23 We have repeated this anal-
ysis for the present article (Table 7). The
variance from birth to 2 years of age
within a geographic area is 8 times larger
than that among geographic areas
(Table 7). Hence, it is very unlikely that
variability among geographic areas ex-
plains >10% of the total variability in
infant and child length in healthy, well-
nourished, low-risk populations who
receive adequate healthcare. These re-
sults are in very close agreement with the
data from the WHO Child Growth
Standards for children <5 years of age,
where the variability within study sites
explained 70% of the total variance as
opposed to a ﬁgure of 3.4% that is
explained by the between-study sites
variability.23
This clinical/epidemiologic ﬁnding is
of great biologic interest because it is
TABLE 4
Morbidity of children who were included in the INTERGROWTH-21st Preterm
Postnatal Growth Standards22 at 1 and 2 years of age
Medical condition
1 Year of age
(n¼154), n (%)
2 Years of age
(n¼143), n (%)
Hospitalized at least once 34 (22.1) 7 (4.9)
Total number of days hospitalized 5 (3e8)a 7 (3e9)a
Any prescription made by a
healthcare professional
98 (63.6) 72 (50.3)
Antibiotics (3 regimens) 31 (20.1) 12 (8.4)
Iron/folic acid/vitamin
B12/other vitamins
56 (36.4) 23 (16.1)
Up-to-date with local
vaccination policies
139 (90.3) 136 (95.1)
Otitis media/pneumonia/
bronchiolitis
13 (8.4) 7 (4.9)
Parasitosis/diarrhea/vomiting 11 (7.1) 10 (7.0)
Seizures/cerebral palsy/
neurologic disorders
1 (0.6) 0
Exanthema/skin disease 27 (17.5) 21 (14.7)
UTI/pyelonephritis 0 0
Fever 3 d (3 episodes) 11 (7.1) 5 (3.5)
Malaria 0 1 (0.7)
Meningitis 0 0
Other infections that
required antibiotics
2 (1.3) 4 (2.8)
Hearing problems 0 (0.0) 0
Asthma 2 (1.3) 1 (0.7)
Cardiovascular problems 0 1 (0.7)
Blindness 0 0
Gastroesophageal reflux 6 (3.9) 0
Any hemolytic condition 2 (1.3) 2 (1.4)
Any malignancy 1 (0.6) 0
Cow’s milk protein allergy NA 3 (2.1)
Food allergies 1 (0.6) 3 (2.1)
Injury trauma 1 (0.6) 4 (2.8)
Any condition that required surgery 2 (1.3) 4 (2.8)
NA, not applicable (data were not collected at the 1-year follow-up visit); UTI, urinary tract infection.
a Data are given as median (interquartile range).
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consistent with a metaanalysis of 22
genome-wide association studies that
showed that the polygenic scores, based
on 180 single nucleotide polymorphisms
that previously were associated with
adult height, explained only a very small
proportion of the total variance in birth
and infant length (0.13% and 2.95%,
respectively).46
Long-term implications
Our 2-year follow-up evaluation of this
large cohort of healthy children allowed
their mean predicted adult height to be
estimated based on the assumption that
health, nutritional, and socioeconomic
conditions would remain adequate
(Figure 4). Thus, the participants in the
low-middle income countries sites (and
by implication those from other similar
countries) are expected to be approxi-
mately 8 cm taller as adults than the
mean height of their parents; these data
are very close to the 6.2e7.8 cm results
that were observed in a similar, second-
ary analysis of the WHO Multicentre
Growth Reference Study database.37
However, because optimal growth
largely has been achieved in the parents
from high-income country sites, their
children are expected to be, on average,
only 2.2 cm taller (Figure 4).
Our results conﬁrm a pattern and
magnitude of apparent transgenera-
tional “washout”47 that has previously
been described in the Multicentre
Growth Reference Study populations.37
This effect on skeletal growth suggests
that a highly sensitive response to
environmental changes (eg, better
intrauterine and infant nutrition and
healthcare) can occur in 1 generation
(ie, in a much shorter timeframe than
evolution allows). The mechanisms,
which may be mediated by modiﬁca-
tions in gene expression that are not
linked to DNA sequence changes, are
being investigated currently at the mo-
lecular level in the INTERBIO-21st
Study.
The observation that this healthy
cohort was at the 58th percentile of the
sex-speciﬁc weight for age of the WHO
Child Growth Standards at 2 years of age
has potential implications in describing
the natural history of becoming over-
weight among healthy infants. Because
we did not implement any speciﬁc
nutritional intervention, other than to
promote breastfeeding, this weight dis-
tribution may represent the initial stages
of the overweight epidemic facing many
urban children who are exposed to
westernized diets. Recent standardized,
prospectively collected, fetal data have
conﬁrmed the complex effect of nutri-
tion, the environment, migration, and
social-cultural issues on fetal growth
patterns.48-50
The short-term shift in weight distri-
bution in an otherwise healthy popula-
tion that we have described also
reinforces the concept that comparisons
among populations to evaluate growth
potential should be based on length
rather than weight because of its sensi-
tivity to acute inﬂuences.
A larger question that goes beyond the
scope of this article relates to the timing,
velocity, and individual tracking of
growth from conception to 2 years of age
vis-à-vis feeding and morbidity in high-
risk populations. The exploration of
these questions in a longitudinal fashion,
including interactions, has considerable
statistical complexity, which we are
presently investigating in the
INTERBIO-21st Study.
In summary, we have presented evi-
dence that the participants who are
enrolled in the international Fetal
Growth Standards and the Preterm
Postnatal Growth Standards of the
INTERGROWTH-21st Project and who
were selected based on the WHO pre-
scriptive approach for growth standards
remain healthy and have adequate
growth and development patterns at the
key milestone of 2 years of age. This is
additional strong conﬁrmation of the
sample’s appropriateness for the con-
struction of international growth stan-
dards. The INTERGROWTH-21st
international standards are freely avail-
able (www.intergrowth21.tghn.org) for
use worldwide.
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Anthropometric measures at 2 years of age of children who were included in the INTERGROWTH-21st Preterm Postnatal
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Variable N
INTERGROWTH-21st
Comparison with World Health
Organization Child Growth Standards
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deviationb
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data.
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FIGURE 3
Median age of achievement (3rd
and 97th percentiles) of 4 gross
motor development milestones
Data are for children who were included in the
INTERGROWTH-21st Fetal Growth Standards21
(purple) and children who were included in the
INTERGROWTH-21st Preterm Postnatal Growth
Standards22 (blue). The diamonds represent the
use of corrected age for the children who were
born preterm. For comparison, the 3rd and 97th
percentiles of the World Health Organization
windows of achievement35 for the same mile-
stones are presented in grey (with the median
shown as a vertical line).
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SUPPLEMENTARY FIGURE
Study flow of INTERGROWTH-21st Preterm Postnatal Follow-up at 2 years
The chart shows the cohort that contributed data to the construction of the INTERGROWTH-21st
Preterm Postnatal Growth Standards.22
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ajog.org OBSTETRICS Original Research
FEBRUARY 2018 American Journal of Obstetrics& Gynecology S854.e1
Downloaded for Anonymous User (n/a) at Aga Khan Hospital from ClinicalKey.com by Elsevier on September 06, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.
SUPPLEMENTARY TABLE 1
Twenty-fourehour dietary intake of children whowere included in the INTERGROWTH-21st Fetal Growth Standards21 at
1 and 2 years of age
Food group given to the child at least once a day 1 Year of age (n¼2832), n (%) 2 Years of age (n¼3041), n (%)
Grains, roots, and tubers 2811 (99.3) 3031 (99.7)
Legumes and nuts 1124 (39.7) 1375 (45.2)
Dairy products 2822 (99.6) 3040 (100.0)
Flesh foods 1676 (59.2) 2083 (68.5)
Eggs 575 (20.3) 889 (29.2)
Vitamin-A-rich fruits 1907 (67.3) 1950 (64.1)
Other fruits and vegetables 2606 (92.0) 2863 (94.1)
Fats: spreads/oils 885 (31.3) 1342 (44.1)
Sugars: sweets/sugar products/jelly/sweetened drinks 435 (15.4) 989 (32.5)
Villar et al. Validation of the INTERGROWTH-21st fetal growth standards. Am J Obstet Gynecol 2018.
SUPPLEMENTARY TABLE 2
Twenty-fourehour dietary intake for children who were included in the INTERGROWTH-21st Preterm Postnatal Growth
Standards22 evaluated at 1 and 2 years of age
Food group given to the child at least once a day 1 Year of age (n¼154) 2 Years of age (n¼143)
Grains, roots, and tubers 153 (99.4) 142 (99.3)
Legumes and nuts 54 (35.1) 68 (47.6)
Dairy products 154 (100.0) 143 (100.0)
Flesh foods 95 (61.7) 101 (70.6)
Eggs 35 (22.7) 35 (24.5)
Vitamin-A-rich fruits 104 (67.5) 84 (58.7)
Other fruits and vegetables 130 (84.4) 133 (93.0)
Fats: spreads/oils 34 (22.1) 55 (38.5)
Sugars: sweets/sugar products/jelly/sweetened drinks 14 (9.1) 45 (31.5)
Villar et al. Validation of the INTERGROWTH-21st fetal growth standards. Am J Obstet Gynecol 2018.
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